Patents Issued in April 3, 2014
-
Publication number: 20140093539Abstract: Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA), in an amount less than 1 ?g.Type: ApplicationFiled: December 5, 2013Publication date: April 3, 2014Applicant: Protalex, Inc.Inventor: Paul Mann
-
Publication number: 20140093540Abstract: Immunogenic compositions and vaccines against Plasmodial infection comprising an Rh polypeptide or a fragment or variant thereof are disclosed. Also disclosed are Rh5 polypeptides or fragments or variants thereof capable of binding CD147 and conferring protection against infection and/or disease caused by multiple Plasmodial strains or Plasmodial species, inhibitors of the interaction between Rh5 and CD147 and methods for producing polypeptides in a mammalian expression system.Type: ApplicationFiled: October 7, 2011Publication date: April 3, 2014Applicant: Genome Research LimitedInventors: Gavin J. Wright, Julian C. Rayner, Cecile Crosner, Leyla Y. Bustamante, S. Josefin Bartholdson
-
Publication number: 20140093541Abstract: The present invention relates to oral immunotherapy for the desensitisation of patients who are hypersensitive to peanut allergen. The immunotherapy comprises increasing the oral dose daily dose of peanut protein administered to the patient at intervals of at least 2 weeks in a series of increments from an initial dose to a maximum dose, the series of dose increments including 2 mg, 5 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg and 800 mg; administering a daily oral dose of the maximum dose of peanut protein for at least 2 years and then administering a weekly oral dose of the maximum dose of peanut protein for at least 2 years.Type: ApplicationFiled: March 16, 2012Publication date: April 3, 2014Applicants: CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION, CAMBRIDGE ENTERPRISE LIMITEDInventors: Andrew Clark, Pamela Ewan
-
Publication number: 20140093542Abstract: Embodiments of the inventions relate to modulating NFAT activity, modulating store-operated Ca2+ entry into a cell and treating and/or preventing hyperactivity or inappropriate immune response by inhibiting the expression or activities of septin 4 (SEPT 4) and septin 5 (SEPT 5) proteins involved in the calcineurin/NFAT axis and T-cell activation.Type: ApplicationFiled: October 10, 2011Publication date: April 3, 2014Applicant: IMMUNE DISEASE INSTITUTE, INC.Inventors: Anjana Rao, Patrick Hogan, Sonia Sharma
-
Publication number: 20140093543Abstract: A vacuum container supports a cancellous device fully immersed within a solution of a bone growth promoting substance in a sealed chamber. The solution may include one of a Demineralized Bone Matrix (DBM) solution, a morphegenic protein solution, or a stem cell solution. A vacuum creating device is in fluid communication with the sealed chamber, and is operable to remove air from within the sealed chamber to create a vacuum therein. Removing air from the sealed chamber also removes air from a plurality of voids in the cancellous device, which allows the solution to fill the voids and saturate the cancellous device in preparation for use as a bone graft.Type: ApplicationFiled: October 2, 2012Publication date: April 3, 2014Inventor: Vittorio M. Morreale
-
Publication number: 20140093544Abstract: A solid oral sensorial product includes at least one botanical material and at least one phosphate containing stain inhibitor. The botanical material is selected from the group consisting of tobacco, tea, coffee, cocoa, and combinations thereof.Type: ApplicationFiled: September 20, 2013Publication date: April 3, 2014Applicant: Philip Morris USA Inc.Inventors: Donald E. Miser, William R. Sweeney, Qinglin Li, Jerome A. Merski
-
Publication number: 20140093545Abstract: The present invention refers to a pharmaceutical preparation for use as an antibacterial agent, where the pharmaceutical preparation is prepared by a method comprising the steps of bringing a full blood sample taken from a patient in contact with a vessel or container and incubating the sample.Type: ApplicationFiled: September 26, 2013Publication date: April 3, 2014Applicant: ORTHOGEN AGInventors: Maria-Paz Weisshaar, Julio Reinecke, Peter Wehling
-
Publication number: 20140093546Abstract: A porous silicon implant impregnated with a beneficial substance, such as a micromineral required for healthy physiology, is implanted subcutaneously and is entirely corroded away over the following months/year to release the beneficial substance in a controlled manner. In a second embodiment the implant may have a large number of holes which contain beneficial substance and which are closed by bio-erodible doors of different thickness so as to stagger the release of the beneficial substance over time as the doors are breached.Type: ApplicationFiled: December 4, 2013Publication date: April 3, 2014Applicant: sPiMedical LimitedInventors: Leigh T. Canham, Christopher P. Barrett, Timothy I. Cox, Peter J. Wright, Andrew P. Bowditch
-
Publication number: 20140093547Abstract: The invention relates to a method for the production of silicone in water emulsions by emulsion polymerisation. The emulsion contains particles of an organopolysiloxane polymer having an average particle diameter of less than 1 ?m. The method comprises: —combining a silanol end-blocked organosiloxane starting polymer, water, and a surfactant; said starting polymer having a viscosity of at least 2 Pa·s preferably at least 2.5 Pa·s preferably at least 3.5 Pa·s preferably at least 4 Pa·s and up to 150 Pa·s; —emulsifying the starting polymer by agitating or shearing the ingredients; —polymerizing the starting polymer to form a longer chain silanol end-blocked organopolysiloxane polymer; wherein at least a portion of said polymerising step is performed at a temperature of less than or equal to 16° C. preferably less than or equal to 15° C.Type: ApplicationFiled: March 1, 2012Publication date: April 3, 2014Inventors: Severine Cauvin, Sophie Hanssens, Alberto Petrosino, Benoit Rassart, Blondine Van Roy
-
Publication number: 20140093548Abstract: The present invention provides a method of decontaminating human skin from noxious substances without a washing and/or massage procedure, wherein the method comprises applying a textile composite to a contaminated skin area for a predetermined period of time, wherein a washing procedure or a massage procedure is not utilized; and removing the textile composite from the contaminated skin area.Type: ApplicationFiled: November 8, 2013Publication date: April 3, 2014Applicant: SNS Nano Fiber Technology, LLCInventors: Jurgen Lademann, Laura M. Frazier, Woraphon Kataphinan
-
Publication number: 20140093549Abstract: An adhesion inhibiting surgical barrier. The surgical barrier includes a wound-facing polymeric coating comprising an enteric polymer; and at least one flexible substrate, the at least one flexible substrate having at least one exterior surface, wherein the polymeric coating is applied to the at least one flexible substrate to substantially cover the at least one exterior surface thereof. A method of inhibiting the formation of adhesions in a patient who has undergone a surgical procedure and a method of repairing a gastric or duodenal perforation are also described herein.Type: ApplicationFiled: December 2, 2013Publication date: April 3, 2014Applicant: Ethicon, Inc.Inventors: Robert W. Van Holten, Jagdishchandra C. Patel
-
Publication number: 20140093550Abstract: A system of stabilized metallic nanoparticles is described that includes metallic nanoparticles coated with a hydrophilic polymer that has been reacted with a catechol-based ligand. Also described are stable, metallic nanoparticles that can be used alone or in conjunction with biocides, antibiotics, or other treatment systems in a method to disrupt a biofilm and facilitate its removal from a surface. The nanoparticles can be metal, such as platinum, silver, iron (II, III) oxide (Fe3O4), and gold. The nanoparticles can be sterically stabilized, such as with a polymer, or charge stabilized, such as with citrate, resulting in nanoparticles having modified surfaces. This surface modification is thought to enhance the stability of the nanoparticles and decrease their likelihood of aggregation, which, in turn, enhances their ability to disrupt and disperse existing biofilms.Type: ApplicationFiled: October 3, 2013Publication date: April 3, 2014Applicant: Clemson UniversityInventors: Tamara L. McNealy, Olin Thompson Mefford, IV, Steven L. Saville
-
Publication number: 20140093551Abstract: Provided is a photocatalytic composition comprising zinc (Zn) doped titanium dioxide (TiO2) nanoparticles, wherein the ratio of titanium dioxide nanoparticles to zinc is from about 5 to about 150. The photocatalytic composition absorbs electromagnetic radiation in a wavelength range from about 200 nm to about 500 nm, and the absorbance of light of wavelengths longer than about 450 nm is less than 50% the absorbance of light of wavelengths shorter than about 350 nm. Further provided is a method for treating or preventing microbial diseases and infestations in a plant and a method for increasing crop yield of a plant by applying the photocatalytic compositions taught herein to the surface of a plant. Also provided is a method for treating microbial diseases on a surface by applying the photocatalytic compositions taught herein to a surface illuminated by artificial light.Type: ApplicationFiled: November 1, 2013Publication date: April 3, 2014Inventors: Stewart Benson Averett, Devron R. Averett
-
Publication number: 20140093552Abstract: Microparticles are prepared by a method that includes: (a) forming a layer comprising a first polymer on a solid surface by depositing a first composition one or more times on the solid surface, wherein the first composition comprises the first polymer and a first solvent, and evaporating the first solvent in the first composition; (b) forming one or more layers comprising a second polymer and a therapeutic agent by depositing a second composition on all or part of the layer formed in step (a), wherein the second composition comprises the second polymer, the therapeutic agent, and a second solvent; and evaporating the second solvent in the second composition; and (c) forming an additional layer comprising a third polymer by depositing a third composition one or more times on a previously formed layer, wherein the third composition comprises the third polymer and a third solvent; and evaporating the third solvent in the third composition.Type: ApplicationFiled: September 20, 2013Publication date: April 3, 2014Applicant: SKS Ocular, LLCInventors: Nikita Malavia, Robert Jennings, Chris Rhodes, Laxma Reddy, Norman Betty
-
Publication number: 20140093553Abstract: An elongate body for parenteral injection at low velocity from a device is described. The body has at least one pointed end and comprises at least one active material. In addition, the body has a compressive strength of greater than or equal to 5 Newton and the pointed end has an included angle of between about 10-50°. A solid vaccine formulation for needle-free parenteral delivery, methods for making the body, packaging of the body and use of the body, packaging and suitable delivery device are also described.Type: ApplicationFiled: December 3, 2013Publication date: April 3, 2014Inventors: Charles David Ogilvy POTTER, Shohre NABAHI
-
Publication number: 20140093554Abstract: The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a large lipid globule size. The composition can be used to increase bone mineral content and/or bone mass density.Type: ApplicationFiled: June 10, 2013Publication date: April 3, 2014Inventors: Eline Marleen VAN DER BEEK, Gelske SPEELMANS, Antonie VAN BAALEN, Annemarie OOSTING, Günther BOEHM
-
Publication number: 20140093555Abstract: The present invention provides a patch preparation containing a support and an adhesive layer on at least one surface of the support, wherein the adhesive layer contains a drug, amine oxide, a low-polar liquid component based on an organic compound having an angle of 0-19° as calculated by the formula (I): angle(°)=arctan(inorganic value/organic value)×(180/?) and using an inorganic value and an organic value on an organic conceptual diagram, and an adhesive base, and the adhesive layer has an amine oxide content of 0.1-5 wt % and a low-polar liquid component content of 30-50 wt %.Type: ApplicationFiled: September 27, 2013Publication date: April 3, 2014Inventors: Masato NISHIMURA, Yoshitaka INOUE, Yoshiaki ITO
-
Publication number: 20140093556Abstract: The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV).Type: ApplicationFiled: January 26, 2012Publication date: April 3, 2014Applicants: SANOFI PASTEUR SA, POLYMUNE SCIENTIFIC IMMUNOBIOLOGISCHE FORSCHUNG GMBH, UNIVERSIDAD DE GRANADA, PX' THERAPEUTICSInventors: Francisco Conejero-Lara, Irene Luque, Pedro Luis Mateo, Andreas Wagner, Raphaelle Claude, Marie-Gaelle Roger, Nicolas Mouz, Christophe Martin
-
Publication number: 20140093557Abstract: An exosomal composition is provided that comprises a therapeutic agent encapsulated by an exosome. The therapeutic agent can be a phytochemical agent, a chemotherapeutic agent, or a Stat3 inhibitor. Pharmaceutical compositions comprising the exosomal compositions are also provided. Methods for treating an inflammatory disease or a cancer are further provided and include administering an effective amount of an exosomal composition to a subject in need thereof to thereby treat the inflammatory disorder or the cancer.Type: ApplicationFiled: December 16, 2013Publication date: April 3, 2014Applicant: University of Louisville Research Foundation, Inc.Inventor: Huang-Ge Zhang
-
Publication number: 20140093558Abstract: The present invention relates to crystal modifications of racemic (2R,S)- and enantiomerically pure (2R)-resp. (2S)-DOTAP chloride, to processes for the preparation thereof, and to the use thereof for the preparation of pharmaceutical compositions.Type: ApplicationFiled: May 2, 2012Publication date: April 3, 2014Applicant: MERCK PATENT GMBHInventors: Michael Wilhelm Platscher, Alfred Hedinger
-
Publication number: 20140093559Abstract: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.Type: ApplicationFiled: November 1, 2013Publication date: April 3, 2014Applicant: GRUNENTHAL GMBHInventors: JOHANNES BARTHOLOMAEUS, HEINRICH KUGELMANN
-
Publication number: 20140093560Abstract: The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism.Type: ApplicationFiled: December 3, 2013Publication date: April 3, 2014Applicant: Repros Therapeutics Inc.Inventor: Joseph S. Podolski
-
Publication number: 20140093561Abstract: Provided herein are controlled release oral dosage forms of poorly soluble drugs, methods of making the dosage forms, and methods of their use for the treatment of various diseases and/or disorders.Type: ApplicationFiled: January 9, 2012Publication date: April 3, 2014Applicant: CELGENE CORPORATIONInventors: Ming J. Chen, Ho-Wah Hui, Thomas Lee, Paul Kurtulik, Sekhar Surapaneni
-
Publication number: 20140093562Abstract: The invention provides a composition consisting essentially of a solid naproxen concentrate, wherein the solid naproxen concentrate comprises (a) a solid naproxen free acid and (b) a solid naproxen alkali salt, and wherein at least 90% of the weight of the solid naproxen concentrate is naproxen free acid and naproxen alkali salt, as well methods of producing such a solid naproxen concentrate.Type: ApplicationFiled: December 3, 2013Publication date: April 3, 2014Applicant: Pharmaceutics International, Inc.Inventors: EmadEldin M. Hassan, Sridhar Gumudavelli
-
Publication number: 20140093563Abstract: The present invention relates to an oral pharmaceutical composition of febuxostat which comprises an intragranular component and an extragranular component. Further, it relates to processes for the preparation of said composition and a method of using said composition.Type: ApplicationFiled: December 5, 2013Publication date: April 3, 2014Applicant: RANBAXY LABORATORIES LIMITEDInventors: Abhishek SRIVASTAVA, Surajit N. DAS, Mukesh Kumar GARG, Ajay Kumar SINGLA, Amit GUPTA, Prakash A. JADHAV
-
Publication number: 20140093564Abstract: The present invention is directed to novel pharmaceutical compositions comprising fixed dose combinations of a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor), or a pharmaceutically acceptable salt thereof, and simvastatin, or pharmaceutically acceptable salt thereof, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes and hypercholesterolemia with such pharmaceutical compositions. In particular, the invention is directed to pharmaceutical compositions comprising fixed-dose combinations of sitagliptin phosphate and simvastatin.Type: ApplicationFiled: June 8, 2012Publication date: April 3, 2014Applicants: MERCK SHARP & DOHME LTD., Merck Sharp & Dohme CorpInventors: Kathryn Bradley, Richard Elkes, Shaun Fitzpatrick, Robert Saklatvala, Mustafa Mohamed, Richard Kendall
-
Publication number: 20140093565Abstract: The invention relates to a pharmaceutical composition comprising a HDAC inhibitor, a pharmaceutically acceptable acid or a salt thereof or a mixture thereof and a steroid or a pharmaceutically acceptable salt thereof as well use of said pharmaceutical composition for the treatment of cancer as a pretreatment prior to other treatments. Said HDAC inhibitor or steroid may alternatively be administrated separately prior to additional treatments.Type: ApplicationFiled: March 20, 2012Publication date: April 3, 2014Applicant: VALCURIA ABInventors: Kristina Drott, Thomas Relander
-
Publication number: 20140093566Abstract: Provided herein are pharmaceutical formulations, comprising 4-((9-((3S)-tetrahydro-3-furanyl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)-trans-cyclohexanol, including pharmaceutically acceptable salts, solvates, isomers, isotopologues, tautomers and racemic mixtures thereof, and a pharmaceutically acceptable excipient; and their use for treating or preventing disease.Type: ApplicationFiled: November 8, 2013Publication date: April 3, 2014Applicant: Signal Pharmaceuticals, LLCInventors: Sreenivas S. Bhat, Xiaozhong Liang, Anthony Tutino, Anthony Joseph Frank
-
Publication number: 20140093567Abstract: A method for easily producing orodispersible tablets that secure an eluting behavior of a principal agent in the digestive tract and mask unpleasant taste in the oral cavity is provided. Provided is a method for producing orodispersible tablets which includes mixing an additive to a principal agent to form principal agent particles as a granulation process, coating the principal agent particles with a coating agent to form coated particles as a coating process, and tableting the coated particles to form tablets as a tableting process, wherein the additive used in the granulation process contains a pH regulator, and the coating agent used in the coating process contains a pH-dependent polymer dissolving at pH 5 or more.Type: ApplicationFiled: June 8, 2012Publication date: April 3, 2014Applicant: NIPRO CORPORATIONInventors: Yohei Hoashi, Naohisa Katayama, Shunsuke Daidouji
-
Publication number: 20140093568Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.Type: ApplicationFiled: August 15, 2013Publication date: April 3, 2014Applicant: Genentech, Inc.Inventors: Gordon Bray, Iris Chan
-
Publication number: 20140093569Abstract: A pharmaceutical composition for controlled release of an active substance is provided. The active substance is released into an aqueous medium by erosion of at least one surface of the composition. The composition comprises i) a matrix comprising a) polymer or a mixture of polymers, b) an active substance and, optionally, c) one or more pharmaceutically acceptable excipients, and ii) a coating.Type: ApplicationFiled: August 23, 2013Publication date: April 3, 2014Applicant: EGALET LTD.Inventors: Gina Fischer, Daniel Bar-Shalom, Lillian Slot, Christine Andersen
-
Publication number: 20140093570Abstract: The present disclosure relates to crystalline form of (S)—N—((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluorobenzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, salts and hydrates thereof. This disclosure also relates to solid oral formulation of (S)—N—((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, pharmaceutically acceptable salts, solvates (including hydrates) thereof, as well as methods of treatment using the same.Type: ApplicationFiled: December 3, 2013Publication date: April 3, 2014Applicant: Novartis AGInventors: Jeewan Thakur, Dong Yang, Lili Feng
-
Publication number: 20140093571Abstract: A kneadable and moldable bone-replacement material includes a mixture of calcium-containing ceramic particles and a hydrogel or a substance which can be swelled into a hydrogel. The ceramic particles are of fully synthetic origin and the individual ceramic particles have a structure which is at least partially cohesive and porous. In addition, the majority of the ceramic particles have a non-spheric shape.Type: ApplicationFiled: December 9, 2013Publication date: April 3, 2014Inventors: Giancarlo Rizzoli, Thierry Stoll, Reto Luginbuhl, Marc Bohner
-
Publication number: 20140093572Abstract: A method, composition and structure to treat fouling. In one embodiment, the method of treating fouling includes providing a structure including a first component of a base material and a second component of an energetically activated nanostructure, and applying a stimuli to the structure that effectuates an increase or decrease in the temperature of the energetically activated nanostructure. The increase or decrease in the temperature of the energetically activated nanostructure modifies the chemical and/or mechanical properties of the base material. The modifications to the chemical and/or mechanical properties of the base material obstruct fouling of the structure.Type: ApplicationFiled: May 4, 2012Publication date: April 3, 2014Applicant: UT-BATTELLE, LLCInventors: Mitchel J. Doktycz, David P. Allison, Charles F. Barnett, Scott T. Retterer
-
Publication number: 20140093573Abstract: A non-enteric coated pharmaceutical composition having an enhanced bioavailability comprising an acid-labile active ingredient and a nanolized biocompatible polymer, wherein the acid-labile active ingredient is mixed with and trapped by the nanolized biocompatible polymer, and the acid-labile active ingredient is sustainably released from the nanolized biocompatible polymer.Type: ApplicationFiled: September 28, 2012Publication date: April 3, 2014Applicant: National Taiwan UniversityInventors: Wen Jen LIN, Milind Alai
-
Publication number: 20140093574Abstract: The present invention relates to solid dispersions including, but not limited to, co-processed carbohydrates with different solubilities and concentrations, which have a microcrystalline plate structure. The solid dispersions, excipient systems and formulations of the present invention are highly compactable and durable and when compressed into solid dosage forms demonstrate uniform densification, low friability at low pressures, and and/or relatively constant low disintegration times at various hardnesses. The solid dosage forms of the present invention demonstrate superior organoleptics, disintegration, and/or robustness.Type: ApplicationFiled: December 5, 2013Publication date: April 3, 2014Applicant: SPI Pharma, Inc.Inventors: John Tillotson, Cecil Propst
-
Publication number: 20140093575Abstract: Systems and methods for coating a particle core with a layer-by-layer film are disclosed.Type: ApplicationFiled: April 23, 2013Publication date: April 3, 2014Applicant: Massachusetts Institute of TechnologyInventor: Massachusetts Institute of Technology
-
Publication number: 20140093576Abstract: The present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising: a. a safe and effective amount of a therapeutically active agent; b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and c. an outer coating layer comprising an enteric polymer or film coating material; wherein the inner coating layer is not the same as the outer coating layer; wherein if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2; and wherein the inner coating layer and the outer coating layer do not contain any therapeutically active agent.Type: ApplicationFiled: October 11, 2013Publication date: April 3, 2014Applicant: Warner Chilcott Company, LLCInventors: Gregory Paul Dittmar, Joseph Michael Amante, Tony Ryan Cronk, Daniel Gary Newby
-
Publication number: 20140093577Abstract: The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles.Type: ApplicationFiled: October 3, 2013Publication date: April 3, 2014Applicant: NEOS THERAPEUTICS, LPInventors: Mark TENGLER, Paul Taskey, Daniel Lockhart, Russell McMahen
-
Publication number: 20140093578Abstract: An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile with a single peak, wherein said oral clonidine dosage unit provides a therapeutically effective plasma concentration for at least about 70%, or at least 85% of the twenty-four hour period following the single dose administration. Both liquid and solid formulations are provided, as are methods of treating a patient by a single administration of a formulation of the invention so as to achieve a therapeutic effect for 24-hours.Type: ApplicationFiled: November 26, 2013Publication date: April 3, 2014Applicant: Tris Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu
-
Publication number: 20140093579Abstract: The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a ?-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours.Type: ApplicationFiled: December 9, 2013Publication date: April 3, 2014Applicant: BIND Therapeutics, Inc.Inventors: Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
-
Publication number: 20140093580Abstract: The present invention provides for novel sustained release silk-based delivery systems. The invention further provides methods for producing such formulations. In general, a silk fibroin solution is combined with a therapeutic agent to form a silk fibroin article. The article is then treated in such a way as to alter its conformation. The change in conformation increases its crystallinity or liquid crystallinity, thus controlling the release of a therapeutic agent from the formulation. This can be accomplished as single material carriers or in a layer-by-layer fashion to load different therapeutic agents or different concentrations of these agents in each layer.Type: ApplicationFiled: December 3, 2013Publication date: April 3, 2014Applicants: EIDGENOSSISCHES TECHNISCHE HOCHSCHULE (THE SWISS FEDERAL INSTITUTE OF TECHNOLOGY), TRUSTEES OF TUFTS COLLEGEInventors: David L. Kaplan, Lorenz Meinel
-
Publication number: 20140093581Abstract: A method for treating or preventing microbial skin infections comprising the step of: administering to a subject in need thereof a composition comprising avian extract EP-2 in a therapeutically effective concentration together with a pharmaceutically acceptable carrier and/or diluent.Type: ApplicationFiled: May 2, 2012Publication date: April 3, 2014Applicant: COCKY SMART PTY LTDInventor: John Chamberlain
-
Publication number: 20140093582Abstract: Serum compositions for application to endothelial tissue are described which contain an amniotic fluid extract in combination with embryonic stem cells. Formulations containing the serum composition are also described. The serum compositions and formulations may be used to treat conditions of the mouth such as dry mouth and mouth sores.Type: ApplicationFiled: September 24, 2013Publication date: April 3, 2014Applicant: Golden Pearl Investment LLCInventor: Jin Qian
-
Publication number: 20140093583Abstract: The present invention relates to a topical pharmaceutical composition comprising povidone-iodine, a tertiary amide, surfactant and coconut oil, useful for killing microbes and treating wounds or sores on the surface of the skin.Type: ApplicationFiled: June 13, 2013Publication date: April 3, 2014Inventor: Griscom BETTLE, III
-
Publication number: 20140093584Abstract: The present invention provides a method of testing a dog to determine the likelihood that the dog is protected from liver copper accumulation, comprising detecting in a sample the presence or absence in the genome of the dog of one or more polymorphisms selected from (a) SNP ATP7a_Reg3_F_6 (SEQ ID NO:142) and (b) one or more polymorphisms in linkage disequilibrium with (a).Type: ApplicationFiled: September 9, 2013Publication date: April 3, 2014Applicant: MARS, INCInventors: PAUL GLYN JONES, ALAN JAMES MARTIN
-
Publication number: 20140093585Abstract: The present invention relates to the method of treating chemotherapy-induced neuropathy in a subject in need thereof with the use of a poly(ADP-ribose)polymerase (PARP) inhibitor.Type: ApplicationFiled: December 5, 2013Publication date: April 3, 2014Inventors: Vincent L. Giranda, Alexander R. Shoemaker, Kaitlin E. Browman, Shailen K. Joshi, Jill-Desiree Brederson
-
Publication number: 20140093586Abstract: Disclosed are oral rehydration compositions with sucrose, or alternatively fructose and glucose in a 1:1 ratio. The compostion further comprises an osmolarity of below 250 mOsm/L, and sodium below 75 meq/L. Further disclosed are methods of treatment using the same.Type: ApplicationFiled: September 24, 2013Publication date: April 3, 2014Applicant: Drip Drop, Inc.Inventor: Eduardo P. DOLHUN
-
Publication number: 20140093587Abstract: The compositions and methods of this invention relate to peelable film-forming compositions that may be applied to and removed from the skin containing polyvinyl alcohols and adhesion-enhancing polymers.Type: ApplicationFiled: September 28, 2012Publication date: April 3, 2014Inventors: Prashant Bahadur, Jeffrey M. Wu, Kamesh R. Yerramilli
-
Publication number: 20140093588Abstract: The present invention provides methods of reducing the cytotoxic effects of nitric oxide and sulfides comprising coadministering nitric oxide with sulfide. In addition, the present invention provides novel pharmaceutical compositions comprising both nitric oxide and sulfide. The methods and compositions of the present invention may be used in the treatment or prevention of a variety of diseases and disorders, and also in the prevention of cell or tissue damage, including that resulting from ischemia or hypoxia.Type: ApplicationFiled: March 28, 2013Publication date: April 3, 2014Applicant: Fred Hutchinson Cancer Research CenterInventors: Csaba Szabo, Kevin James Tomaselli